The effectiveness of Mexidol in a comorbid patient: with arterial hypertension, coronary heart disease, brain ischemia

Time codes:
  • 00:00

    Comorbid patient and his features

  • 00:52

    The effect of metabolic syndrome on the brain 

  • 01:00

    The risks of polypragmasia 

  • 01:20

    Chronic brain ischemia and its combination with other symptoms

  • 02:11

    Multimodal effects for patients with metabolic syndrome

Ekusheva Evgenia Viktorovna - MD, professor, head. Department of Nervous Diseases and Neurorebition of the Academy of Postgraduate Education of the Federal State Budgetary Educational Institution of the FGBC FMBA of Russia

Announcement:

Comorbid patient is a patient who is faced with a doctor of almost any specialty. Such patients differ in the presence of several chronic diseases at once. Especially often comorbid patients are found among the elderly. A classic example of such a patient is a patient with metabolic syndrome. It combines several conditions, including arterial hypertension, obesity, dyslipidemia and diabetes. The patient’s brain with metabolic syndrome is especially susceptible to pathological processes. Therefore, one of the main tasks of doctors is the protection of this neuronal structure. Mexidol® often becomes an assistant in solving this problem. The use of Mexidol® for ischemia , hypertension and other diseases contributes to the prevention of complications.

Block of articles on this topic

International multicenteric randomized double-tied placebo-controlled study of evaluating the effectiveness and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol® and Mexidol® Forte 250 (study of memo): Subanalysis results in patients with arterial hypertension

Authors:
V.V. Zakharov 1 , O.D. Ostroumova 1.2 , A.I. Kochetkov 2 , M.V. Klepikov 2 , A.I. Fedin 3

The results of clinical studies of the effectiveness and safety of the use of ethylmethylhydroxypyridine of succinate in patients with chronic brain ischemia

Authors:
M.V. Zhuravleva 1.2 , P.R. Kamchatnov 3 , N.S. Vasyukova 4 , V.V. Arkhipov 1 , E.V. Kuznetsova 5 , TR Kameneva 6 , S.Yu. Serebrova 1.2

Mexidol® and Mexidol® Fort 250 as part of the sequential therapy for cognitive disorders in comorbide patients with joint pathology against the background of arterial hypertension and coronary heart disease

Authors:
L.N. Eliseeva, S.V. Kartashova

FSBEI in Kuban State Medical University of the Ministry of Health of Russia, Krasnodar

The influence of Mexidol on the improvement of cognitive status and quality parameters as part of the complex therapy of patients with chronic heart failure of the II - III functional class

Author:
V.V. Tolkacheva, L.V. Karapetyan, N.I. Khutsishvili, S.A. Galochkin, E.R. Kazamedov, railway Kobalava

FGAOU in Russian University of Friendship of Peoples named after Patrice Lumumba, Moscow, Russia

Mexidol effects in patients with chemical and heart failure II - III functional class

Authors:
A.V. Schulkin 2 , E.R. Kazamedov 1 , S.A. Galochkin 1 , V.V. Tolkacheva 1 , railway Cobalava 1

1 FGAOU in Russian University of Friendship of Peoples, Moscow;
2 FSBEI in the Ryazan State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia, Ryazan

Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.

Source of photos and images Shutterstock.com